This page collects WhisperX intelligence signals tagged #biopharma. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Merck is making a massive $6.7 billion strategic move to secure its oncology future, announcing its intent to acquire Terns Pharmaceuticals. The deal, priced at $53 per share, represents a 6% premium and targets Terns' crown jewel: the promising leukemia treatment TERN-701. This acquisition is a direct response to the ...
Grifols SA is pursuing a massive financial maneuver that could see its US biopharma unit valued at nearly four times the size of its parent company. The Spanish plasma giant aims to raise up to $5 billion through an initial public offering of its Los Angeles-based subsidiary, a move that signals a profound strategic sh...
Incyte Corporation has filed an 8-K form with the SEC, disclosing significant changes to its executive leadership and compensation structure. The filing, submitted on March 26, 2026, centers on the departure of directors or certain officers, the election of new directors, and the appointment of new officers, alongside ...
Artelo Biosciences, Inc. has filed a significant 8-K form with the SEC, signaling multiple material corporate developments. The filing, submitted on March 26, 2026, includes disclosures under Item 1.01 for entering into a material definitive agreement, Item 3.02 for an unregistered sale of equity securities, and Item 7...
The European Medicines Agency (EMA) has accepted the marketing authorization application for taletrectinib, a targeted therapy for non-small cell lung cancer (NSCLC) developed by Nuvation Bio and Eisai. This regulatory milestone signals a critical step forward for the drug's potential entry into the European market, pl...
Iterum Therapeutics plc has filed a critical 8-K form with the SEC, triggering a cascade of corporate distress signals. The filing formally discloses a bankruptcy or receivership event under Item 1.03, confirming a severe financial crisis. Simultaneously, Item 2.04 reveals that a triggering event has accelerated or inc...
AnaptysBio, Inc. has filed a significant 8-K form with the SEC, signaling a series of material corporate developments. The filing, submitted on March 27, 2026, encompasses multiple critical items including the entry into and termination of material definitive agreements, changes in its officer and director ranks, and a...
Pulmatrix, Inc. has filed a comprehensive 8-K form with the SEC, detailing a series of material corporate events that collectively signal a significant restructuring of the company. The filing, submitted on March 27, 2026, lists multiple critical items including a change in control, unregistered equity sales, and amend...
OnKure Therapeutics, Inc. has filed a significant 8-K form with the SEC, disclosing multiple material events that signal a period of active corporate restructuring and financial activity. The filing, submitted on March 30, 2026, encompasses a definitive agreement, unregistered securities sales, and changes to its board...
Connect Biopharma Holdings Ltd has filed a significant 8-K form with the SEC, disclosing multiple material events that signal a period of active corporate restructuring and capital activity. The filing, submitted on March 30, 2026, includes entries for entering into a Material Definitive Agreement, conducting Unregiste...
InMed Pharmaceuticals Inc. has been formally notified by The Nasdaq Stock Market that it is not in compliance with a critical listing standard, triggering a potential delisting. The company's common stock failed to maintain a minimum bid price of $1.00 per share over a consecutive 30-day trading period, a violation of ...
Takeda Pharmaceuticals, Massachusetts' largest biopharma employer, is initiating a significant workforce reduction at its Cambridge hub, with nearly 250 layoffs slated to begin this July. The cuts, disclosed in a state filing, will impact all affected employees at the company's 500 Kendall Street location, with some te...
SCYNEXIS, INC. has formally notified the U.S. Securities and Exchange Commission of a significant corporate transaction. The company's 8-K filing, submitted on March 31, 2026, details the completion of an asset acquisition and the entry into a material definitive agreement, signaling a pivotal shift in its operational ...
Iterum Therapeutics plc has been formally notified by The Nasdaq Stock Market that its securities will be delisted, triggering an immediate suspension of trading. The company disclosed the notification in an 8-K filing, citing a failure to satisfy a continued listing rule or standard. This regulatory action represents ...
Cadrenal Therapeutics, Inc. has filed a significant 8-K form with the SEC, disclosing multiple material corporate events in a single filing. The company has entered into a material definitive agreement, conducted an unregistered sale of equity securities, and materially modified the rights of its security holders. Thes...
Biogen has made a decisive $5.6 billion move to acquire Apellis Pharmaceuticals, marking one of its largest-ever acquisitions. The deal is a strategic pivot to significantly expand Biogen's portfolio in immunology and rare disease treatments, signaling a major investment in a high-value therapeutic area. This acquisiti...
Vistagen Therapeutics has been formally notified by Nasdaq that it is not in compliance with a continued listing rule, triggering a potential delisting from the exchange. The biopharmaceutical company disclosed the notice in an 8-K filing, a critical regulatory step that signals significant financial or operational dis...
Silo Pharma, Inc. has filed a Form 8-K with the SEC, disclosing two significant corporate actions that point to a potential strategic pivot or urgent financial maneuver. The filing flags the company's entry into a "Material Definitive Agreement" and the execution of an "Unregistered Sale of Equity Securities," a combin...
Aytu BioPharma has filed a dense 8-K form with the SEC, disclosing a series of significant corporate actions that point to a substantial operational and financial restructuring. The filing, submitted on April 2, 2026, bundles multiple material events, including the entry into a definitive agreement, the reporting of fi...
Kiora Pharmaceuticals has filed a new 8-K form with the SEC, signaling significant internal changes at the executive level. The filing, submitted on April 2, 2026, centers on the departure of directors or certain officers and the appointment of new ones, alongside details of compensatory arrangements for key personnel....